- NEWS EXPLAINER
More Alzheimer’s drugs head for FDA review: what scientists are watching
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 599, 544-545 (2021)
doi: https://doi.org/10.1038/d41586-021-03410-9
References
Mintun, M. A. et al. N. Engl. J. Med. 384, 1691–1704 (2021).
Emanuel, E. J. JAMA 326, 1367–1368 (2021).
Dunn, B., Stein, P. & Cavazzoni, P. JAMA Intern Med. 181, 1276–1278 (2021).
Dunn, B., Stein, P., Temple, R. & Cavazzoni, P. N. Engl. J. Med. 385, 856–857 (2021).